STOCK TITAN

Neumora Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags

Neumora Therapeutics (NMRA) reported a narrower third-quarter 2026 net loss and submitted an investigational drug application for NMRA-215 to the FDA. Net loss was $34.440 million, versus $56.755 million a year earlier; loss per share narrowed to $0.18 from $0.35. Research and development and administrative expenses declined.

Cash and equivalents totaled $85.654 million at September 30, versus $182.530 million at December 31, 2025. Neumora requires substantial additional funding and is evaluating funding options for its lead programs. NMRA-215 produced weight loss of up to 19% alone and up to 26% with semaglutide in obese mice. NMRA-511 at 30 mg twice daily showed dose-proportional exposure versus 20 mg twice daily and no serious adverse events in healthy elderly participants; the program is ready for Phase 2. The NMRA-898 Phase 1 multiple-dose study remains ongoing.

Loading...
Loading translation...
17 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

1 major · 8 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • Moderate pointThird-quarter net loss narrowed to $34.440 million from $56.755 million in 2025.
  • Moderate pointNMRA-215 investigational drug application submitted to the FDA for its obesity development program.
  • Minor pointThird-quarter loss per share narrowed to $0.18 from $0.35 in 2025.
  • Minor pointNine-month net loss narrowed to $130.980 million from $177.478 million in 2025.
  • Minor pointNine-month loss per share narrowed to $0.71 from $1.10 in 2025.
12 minor points
  • Minor pointNMRA-215 preclinical weight loss reached up to 19% alone in diet-induced obese mice.
  • Minor pointNMRA-215 plus semaglutide produced up to 26% weight loss in diet-induced obese mice.
  • Minor pointNMRA-511 at 30 mg twice daily showed no serious adverse events in healthy elderly participants.
  • Minor pointNMRA-511 exposure increased dose-proportionally at 30 mg twice daily versus 20 mg twice daily.
  • Minor point. Forward-looking: it has not happened yet and may not happen.NMRA-511 is ready for Phase 2; Neumora believes the higher dose may improve on Phase 1b efficacy.
  • Minor pointThird-quarter research and development expense fell to $22.614 million from $40.520 million in 2025.
  • Minor pointThird-quarter administrative expense fell to $10.795 million from $12.180 million in 2025.
  • Minor pointThird-quarter acquired in-process research and development expense was zero versus $5 million in 2025.
  • Minor pointNine-month research and development expense fell to $90.495 million from $131.395 million in 2025.
  • Minor pointNine-month administrative expense fell to $37.968 million from $46.281 million in 2025.
  • Minor pointNine-month acquired in-process research and development expense was zero versus $5 million in 2025.
  • Minor pointTotal liabilities declined to $76.495 million at September 30, 2026, from $87.176 million at December 31, 2025.

Negative

  • Major pointSubstantial additional funding is required to continue operations, complete development and, if approved, commercialize product candidates.
  • Moderate pointCash and equivalents declined to $85.654 million at September 30, 2026, from $182.530 million at December 31, 2025.
  • Minor pointStockholders’ equity declined to $18.551 million at September 30, 2026, from $103.871 million at December 31, 2025.
  • Minor pointTotal assets declined to $95.046 million at September 30, 2026, from $191.047 million at December 31, 2025.
  • Minor pointThird-quarter interest expense rose to $1.831 million from $0.747 million in 2025.
3 minor points
  • Minor pointNine-month interest expense rose to $5.505 million from $1.183 million in 2025.
  • Minor pointThird-quarter interest income fell to $0.809 million from $1.685 million in 2025.
  • Minor pointNine-month interest income fell to $2.975 million from $7.009 million in 2025.

News Explained

Neumora provided no updated financial-runway guidance; it says substantial additional funding is needed to operate and develop its candidates, but gives no assurance funding will be available or on what terms.

Key Figures

Weight loss, monotherapy: Up to 19% Weight loss, combination: Up to 26% NMRA-511 dose: 30 mg BID +4 more
Weight loss, monotherapy
Up to 19%
NMRA-215 preclinical diet-induced obesity mouse studies
Weight loss, combination
Up to 26%
NMRA-215 with semaglutide in preclinical diet-induced obesity mouse studies
NMRA-511 dose
30 mg BID
Multiple ascending dose expansion cohort in healthy elderly participants
Serious adverse events
No serious adverse events
NMRA-511 30 mg BID dose
Cash and cash equivalents
$85.7 million
As of September 30, 2026
R&D expense
$22.6 million vs. $40.5 million
Third quarter 2026 vs. third quarter 2025
Net loss
$34.4 million vs. $56.8 million
Third quarter 2026 vs. third quarter 2025

Previous Earnings Reports

1 past event · Latest: Aug 14
Same Type 1 event
  1. Aug 14

    Q2 earnings

    24h Move
    -7.5%

    Prior cash of $116.8 million was expected to fund operations into Q3 2027.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

investigational new drug, multiple ascending dose, nlrp3 inhibitor, positive allosteric modulator
4 terms
investigational new drug regulatory
"submitted an Investigational New Drug (IND) application"
An investigational new drug is a medication that is still being tested in clinical trials to determine if it is safe and effective for treating a specific condition. For investors, it represents a potential breakthrough that could lead to a new treatment and significant financial gains if successful, but also carries risks since it has not yet been approved for widespread use.
multiple ascending dose medical
"results from the multiple ascending dose (MAD) expansion cohort"
A multiple ascending dose is a method used in testing new medicines where small groups of people receive gradually larger amounts of the drug over time. This approach helps researchers find the safest and most effective dose without causing too many side effects. For investors, it signals ongoing steps in drug development that can impact a company's potential success or approval prospects.
nlrp3 inhibitor medical
"a potentially best-in-class, highly brain-penetrant oral NLRP3 inhibitor"
An NLRP3 inhibitor is a substance that blocks a specific part of the body’s immune system responsible for inflammation. By preventing excessive inflammation, it has potential uses in treating certain diseases, which may affect the value of related biotech or pharmaceutical companies. For investors, understanding NLRP3 inhibitors can offer insights into emerging medical therapies and future market opportunities.
positive allosteric modulator medical
"NMRA-898 (M4 Positive Allosteric Modulator)"
A positive allosteric modulator is a drug-like molecule that attaches to a different spot on a biological target than the body’s own messenger, and increases the target’s response when that natural messenger is present—like turning up a volume knob rather than replacing the song. For investors, these agents can boost a therapy’s effectiveness or safety without directly activating the target, offering potential competitive advantage, clearer combination strategies, and distinct patent or regulatory value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

IND application for NMRA-215 (NLRP3 inhibitor) submitted to the U.S. Food and Drug Administration

Dose-proportional increase in exposure observed in multiple ascending dose (MAD) expansion cohort with NMRA-511 (V1aR antagonist), suggesting potential to build on the efficacy profile demonstrated in Phase 1b study

WATERTOWN, Mass., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, today announced financial results for the third quarter ended September 30, 2026, and provided a business update.

“We’ve been in a period of strong execution across our pipeline, including the submission of our IND for NMRA-215 in obesity and the NMRA-511 data we reported today, which suggest we can build on the unsurpassed efficacy seen in our Phase 1b study in AD agitation," said Joshua Pinto, Ph.D., president and chief executive officer, Neumora. “We remain disciplined in allocating capital to the programs with the greatest potential to create value for patients and shareholders, and we are actively evaluating options to fund our lead programs through their next value inflection points.”

KEY PIPELINE HIGHLIGHTS

NMRA-215 (NLRP3 Inhibitor):
Neumora is developing NMRA-215, a potentially best-in-class, highly brain-penetrant oral NLRP3 inhibitor, for the treatment of obesity and cardiometabolic disease and has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration.

Additionally, Neumora today announced the presentation of preclinical results from NMRA-215 at ObesityWeek 2026. The presentation highlighted preclinical findings from diet-induced obesity (DIO) mouse studies of NMRA-215, in which NMRA-215 demonstrated class-leading weight loss of up to 19% as a monotherapy with incretin-like induction and up to 26% in combination with semaglutide.

NMRA-511 (Vasopressin 1a Receptor Antagonist):
Neumora today announced results from the multiple ascending dose (MAD) expansion cohort evaluating a 30 mg BID dose of NMRA-511 in healthy elderly participants. The 30 mg BID dose demonstrated a favorable safety and tolerability profile with no serious adverse events, and dose-proportional increases in exposure compared to the 20 mg BID dose evaluated in the Phase 1b study. The Company believes the 30 mg BID dose may build on the strong efficacy established with the 20 mg BID dose in the Phase 1b study, and the program is Phase 2 enabled.

Additionally, Neumora recently presented data from the NMRA-511 Phase 1b study at the Neuroscience Education Institute (NEI) Fall Congress.

NMRA-898 (M4 Positive Allosteric Modulator):
The Phase 1 MAD study with NMRA-898 in healthy volunteers and patients with stable schizophrenia is ongoing.

THIRD QUARTER 2026 FINANCIAL RESULTS

  • Cash Position: As of September 30, 2026, Neumora had cash and cash equivalents of $85.7 million.
  • Financial Guidance: Neumora is not providing updated financial runway guidance. As disclosed in our Quarterly Report on Form 10-Q being filed with the Securities and Exchange Commission today, to continue to operate our business and complete the development and, if approved, commercialization of our product candidates, we will require substantial additional funding and there can be no assurance such funding will be available to us at all or as to the terms on which are able to obtain such financing.
  • R&D Expense: Research and development expenses for the third quarter of 2026 were $22.6 million, as compared to $40.5 million for the same period in 2025. The decrease was primarily due to a reduction in clinical trial costs, and lower personnel-related costs.
  • G&A Expense: General and administrative expenses for the third quarter of 2026 were $10.8 million, as compared to $12.2 million for the same period in 2025. The decrease was primarily attributable to lower personnel-related costs.
  • Net Loss: The Company reported a net loss of $34.4 million for the third quarter of 2026, as compared to $56.8 million for the same period in 2025.

About Neumora
Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded to confront the greatest medical challenges of our generation by taking a fundamentally different approach to the way treatments for brain diseases are developed. Our therapeutic pipeline currently consists of programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases. Neumora’s mission is to redefine neuroscience drug development by bringing forward the next generation of novel therapies that offer improved treatment outcomes and quality of life for patients.

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements about Neumora Therapeutics, Inc. (the “Company,” “we,” “us,” or “our”) within the meaning of the federal securities laws, including statements related to: Neumora’s intention to redefine neuroscience drug development by bringing forward the next generation of novel therapies that offer improved treatment outcomes and quality of life for patients; the timing, progress and plans for its therapeutic development programs, including the timing of clinical trial initiation and data readouts, including for the NMRA-215, NMRA-511 and NMRA-898 studies; support for continued development, and upcoming milestones and catalysts; expectations and projections regarding future operating results and financial performance, including our ability to continue to operate our business and complete the development and commercialization of our product candidates, if approved; our ability obtain additional funding; and other statements identified by words such as “could,” “expects,” “intends,” “may,” “plans,” “potential,” “should,” “will,” “would,” or similar expressions and the negatives of those terms. Other than statements of historical facts, all statements contained in this press release are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are subject to risks and uncertainties that could cause the actual results to be materially different from the information expressed or implied by these forward-looking statements, including, among others: the risks related to the inherent uncertainty of clinical drug development and unpredictability and lengthy process for obtaining regulatory approvals; risks related to the timely initiation and enrollment in our clinical trials; risks related to our reliance on third parties, including CROs; risks related to serious or undesirable side effects of our therapeutic candidates; risks related to our ability to utilize and protect our intellectual property rights; and other matters that could affect sufficiency of capital resources to fund operations. For a detailed discussion of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Neumora’s business in general, please refer to the risk factors identified in the Company’s filings with the Securities and Exchange Commission (SEC), including but not limited to its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026 which was filed with the SEC on or about the date hereof. Forward-looking statements speak only as of the date hereof, and, except as required by law, Neumora undertakes no obligation to update or revise these forward-looking statements. Our results for the quarter ended September 30, 2026 are not necessarily indicative of our operating results for any future periods.

 
NEUMORA THERAPEUTICS, INC.
Unaudited Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except per share amounts)
         
  Three Months Ended September 30, Nine Months Ended September 30,
  2026
 2025
 2026
 2025
Operating expenses:        
Research and development $22,614  $40,520  $90,495  $131,395 
General and administrative  10,795   12,180   37,968   46,281 
Acquired in-process research and development  —   5,000   —   5,000 
Total operating expenses  33,409   57,700   128,463   182,676 
Loss from operations  (33,409)  (57,700)  (128,463)  (182,676)
Other income (expense):        
Interest income  809   1,685   2,975   7,009 
Interest expense  (1,831)  (747)  (5,505)  (1,183)
Other income (expense), net  (9)  7   44   (498)
Total other income (expense)  (1,031)  945   (2,486)  5,328 
Net loss before income taxes  (34,440)  (56,755)  (130,949)  (177,348)
Provision for income taxes  —   —   31   130 
Net loss $(34,440) $(56,755) $(130,980) $(177,478)
Other comprehensive loss:        
Unrealized gain (loss) on marketable securities  —   24   —   (53)
Comprehensive loss $(34,440) $(56,731) $(130,980) $(177,531)
Net loss per share, basic and diluted $(0.18) $(0.35) $(0.71) $(1.10)
Weighted-average shares outstanding, basic and diluted  187,896   161,838   184,322   161,663 
         


Unaudited Condensed Consolidated Balance Sheets
(in thousands)
     
  September 30, 2026 December 31, 2025
Cash and cash equivalents $85,654 $182,530
Total assets $95,046 $191,047
Total liabilities $76,495 $87,176
Total stockholders’ equity $18,551 $103,871
     

Neumora Contact:
Helen Rubinstein
617-402-5700
Helen.Rubinstein@neumoratx.com 


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What were Neumora Therapeutics’ third-quarter 2026 earnings results?

Neumora reported a $34.440 million net loss, or $0.18 per share, for the quarter ended September 30, 2026. That compares with a $56.755 million net loss, or $0.35 per share, in the same quarter of 2025.

Why did Neumora’s third-quarter 2026 operating expenses decline?

Lower clinical trial and personnel-related costs primarily drove the decline in research and development expenses. Lower personnel-related costs primarily drove the decrease in general and administrative expenses.

Which participants are enrolled in Neumora’s ongoing NMRA-898 study?

The ongoing NMRA-898 Phase 1 multiple ascending dose study includes healthy volunteers and patients with stable schizophrenia.

Keep reading